Oppenheimer Keeps Their Buy Rating on Guardian Pharmacy Services, Inc. Class A (GRDN)

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Guardian Pharmacy Services, Inc. Class A today and set a price target of $35.00.

TipRanks Black Friday Sale

• Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
• Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

According to TipRanks, Wiederhorn is a 5-star analyst with an average return of 10.1% and a 58.72% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as Guardian Pharmacy Services, Inc. Class A, Humana, and Evolent Health.

In addition to Oppenheimer, Guardian Pharmacy Services, Inc. Class A also received a Buy from Truist Financial’s David S Macdonald in a report issued on November 14. However, on November 15, TR | OpenAI – 4o reiterated a Hold rating on Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN).

Based on Guardian Pharmacy Services, Inc. Class A’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $377.43 million and a net profit of $9.82 million. In comparison, last year the company earned a revenue of $314.39 million and had a GAAP net loss of $112.64 million

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GRDN in relation to earlier this year. Most recently, in September 2025, Pharmacy Investors, LLC, an Insider at GRDN sold 964,316.00 shares for a total of $19,440,610.56.